Martin David Harp

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

Additionally, the company also received Clinical Trial Authorization (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Conavi Medical advances intravascular imaging with its Novasight Hybrid system, enhancing coronary disease diagnosis and treatment through new technology.

Character Biosciences enhances its leadership team and secures $93 million in Series B funding to advance treatments for degenerative eye diseases.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

Alteogen received a positive CHMP opinion for EYLUXVI in July 2025.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

The company’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody currently in phase 1b clinical development for patients with either wAMD or DME.

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger agreement.

Kwangdong, a top 5 pharmaceutical and healthcare company in Korea, is actively involved in research and development innovation, including “transformational late-stage, high-impact technologies.”

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

OpZira’s product portfolio includes AdaptDx Pro and the NOVA Vision Testing System.

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.

Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.

The acquisition includes the noninvasive Valeda PBM device for the treatment of early and intermediate dry age-related macular degeneration.

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.

Alfredo Sadun, MD, PhD, details an unexpected outcome from a gene therapy in development for Leber hereditary optic neuropathy (LHON).

In addition to Thompson joining the board of directors, EyeCool also announced the members joining its newly formed medical advisory board (MAB).

Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies.